19:06 , May 22, 2019 |  BC Extra  |  Company News

Management tracks: Gottlieb re-joining NEA; plus Seattle Genetics, Celsius and more

Former FDA Commissioner Scott Gottlieb is joining New Enterprise Associates as a special partner. Gottlieb was a venture partner at the firm from 2007 to 2017. In his new role, Gottlieb will have a “deeper...
23:21 , Apr 11, 2019 |  BC Extra  |  Company News

Management tracks: Prime, Flexion, NodThera, Imara

PBM Prime Therapeutics LLC (Eagan, Minn.) hired Kenneth Paulus as president and CEO, effective May 7. Paulus is an executive adviser at Water Street Healthcare Partners. In 2005-15, Paulus held leadership roles at Minneapolis-based non-profit...
14:46 , Jun 29, 2018 |  BC Week In Review  |  Clinical News

Arsanis discontinues Phase II of lead anti-infective

Arsanis Inc. (NASDAQ:ASNS) discontinued a double-blind, international Phase II trial of lead candidate ASN100 to prevent Staphylococcus aureus pneumonia after a futility analysis showed that the candidate was unlikely to meet its primary endpoint. In...
16:49 , Jun 28, 2018 |  BC Extra  |  Clinical News

Arsanis discontinues Phase II of lead anti-infective, shares plummet

Arsanis Inc. (NASDAQ:ASNS) discontinued a Phase II trial of lead candidate ASN100 to prevent Staphylococcus aureus pneumonia after a futility analysis showed that the candidate was unlikely to meet its primary endpoint. The company's shares...
00:43 , Jan 13, 2018 |  BioCentury  |  Finance

Choosy investors

  Despite losing steam in 4Q17, the broad-based recovery in biotech stocks last year has left investors generally comfortable with current valuations, and hence less optimistic that the sector indexes will outpace the broader market...
21:51 , Dec 5, 2017 |  BC Extra  |  Company News

Pellini joins Section 32

Section 32 named Michael Pellini managing partner. Pellini, who is chairman of cancer molecular profiling company Foundation Medicine Inc. (Cambridge, Mass.), will lead healthcare investments for the firm. Section 32’s portfolio includes infectious disease companies...
19:45 , Nov 17, 2017 |  BC Week In Review  |  Financial News

Arsanis raises $60M IPO and private placement

On Nov. 15, Arsanis Inc. (NASDAQ:ASNS) raised $60 million in an IPO on NASDAQ and a concurrent private placement. The company raised $40 million through the sale of 4 million shares in the IPO underwritten...
18:31 , Nov 16, 2017 |  BC Extra  |  Financial News

Arsanis rises on $60M IPO and private placement

Arsanis Inc. (NASDAQ:ASNS) jumped $4.03 (40%) to $14.03 on its first day of trading Thursday after raising $60 million in an IPO on NASDAQ and a concurrent private placement. The company raised $40 million through...
23:33 , Oct 6, 2017 |  BC Extra  |  Company News

Management tracks: Impel, InGeneron

Drug delivery company Impel NeuroPharma Inc. (Seattle, Wash.) named Jon Congleton president and CEO. He was president and CEO at Nivalis Therapeutics Inc. , which merged with Alpine Immune Sciences Inc. (NASDAQ:ALPN). Regenerative medicine company...
17:56 , Apr 28, 2017 |  BC Week In Review  |  Financial News

Arsanis completes venture financing

On April 26, infectious disease company Arsanis Inc. (Waltham, Mass.) raised $45.5 million in a series D round led by new investor the Bill & Melinda Gates Foundation (Seattle. Wash.). Also participating were new investors...